Growing Infectious Diseases Drive Market Demand

7-Aminocephalosporanic Acid (7-ACA) serves as a crucial component in the production of various antibiotics. These antibiotics are essential for treating a range of infections, including strep throat, pneumonia, ear infections, skin and soft tissue infections, meningitis, urinary tract infections (UTIs), sinus infections, and gonorrhea. As the global population grows, cases of infectious diseases are expected to rise significantly. Consequently, the demand for antibiotics will likely increase, thereby fueling the growth of the 7-ACA market.

For example:

• Pneumonia: Each year, approximately 700,000 children worldwide succumb to pneumonia, highlighting its severity as one of the most common and deadly infectious diseases.
• U.S. Pneumonia Cases: In the United States alone, the CDC reports over 2 million cases of pneumonia annually.
• Gonorrhea in Europe: In Europe, gonorrhea infections in young women aged 20-24 sharply increased in recent years. Between July and December 2022 and January and June 2023, these infections rose by 73% and 89% beyond expected levels across 15 EU/EEA countries.
• Urinary Tract Infections (UTIs): The world’s most common infectious disease, UTIs affect approximately 150 million people globally. In the U.S., recurrent UTIs have a substantial economic impact, costing over $5 billion annually due to the high treatment costs and associated morbidity.

Environmental Challenges in 7-ACA Production

The production of 7-ACA also presents significant environmental challenges. Traditional manufacturing processes generate pollution at various stages, prompting concerns over environmental sustainability. To address these issues, more sustainable production methods are being developed. However, achieving a balance between cost-effectiveness, production efficiency, and environmental responsibility remains complex, as companies navigate the trade-offs required to minimize ecological impact while maintaining market viability.

Recent Developments

• In March 2024, Pfizer Inc. declared that EMBLAVEO® (aztreonam-avibactam) should be granted a marketing authorization after the EMA’s CHMP issued a favorable view. In the event that it is authorized, EMBLAVEO® would be the first combination of β-lactam/β-lactamase inhibitors used to treat severe bacterial infections.
• In December 2023, the debut of FetrojaTM was announced by Shionogi & Co., Ltd. A novel siderophore cephalosporin antibiotic is called Fetroja. The Ministry of Health, Labour, and Welfare approved its marketing and manufacture for a range of illnesses.
• In July 2023, the Chennai-based pharmaceutical manufacturer Orchid Pharma said that, as part of the production-linked incentive (PLI) program, it has joined forces with a top global biotechnology business to transfer knowledge for the fermentation-based “7ACA project.”

Top Companies in the 7-Aminocephalosporanic Acid (7-ACA) Market

• CSPC
• Nectar Lifesciences
• INNER MONGOLIA
• Joincare
• Dragon Pharma
• Fujian Fukang
• Sinopharm Weiqida Pharma
• Shandong Lukang
• Yili Chuangning Biotechnology
• Harbin Pharmaceutical
• CordenPharma
• NCPC

Segments Covered in the Report

By Product

• Enzymatic Hydrolysis
• Chemical Cracking

By Application

• Ceftriaxone
• Cefazolin
• Ceftazidime
• Cefotaxime

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait